MXPA03006412A - Metodos para administrar analogos de epotilona para tratamiento de cancer. - Google Patents

Metodos para administrar analogos de epotilona para tratamiento de cancer.

Info

Publication number
MXPA03006412A
MXPA03006412A MXPA03006412A MXPA03006412A MXPA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
methods
epothilone analogs
administering epothilone
Prior art date
Application number
MXPA03006412A
Other languages
English (en)
Spanish (es)
Inventor
Rebanta Bandyopadhyay
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03006412A publication Critical patent/MXPA03006412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03006412A 2001-01-25 2002-01-22 Metodos para administrar analogos de epotilona para tratamiento de cancer. MXPA03006412A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000601P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA03006412A true MXPA03006412A (es) 2003-10-15

Family

ID=26950348

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006412A MXPA03006412A (es) 2001-01-25 2002-01-22 Metodos para administrar analogos de epotilona para tratamiento de cancer.

Country Status (10)

Country Link
JP (1) JP4633331B2 (pl)
AU (1) AU2002245296B2 (pl)
CA (1) CA2434526C (pl)
HR (1) HRP20030677B1 (pl)
IL (1) IL156578A0 (pl)
MX (1) MXPA03006412A (pl)
NO (1) NO335119B1 (pl)
PL (1) PL207720B1 (pl)
RU (1) RU2292202C2 (pl)
WO (1) WO2002058700A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
SI3002009T1 (sl) * 2007-06-01 2021-09-30 Wyeth Llc Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib
WO2009089138A1 (en) * 2008-01-04 2009-07-16 Bristol-Myers Squibb Company Oral administration of ixabepilone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DE69802536T2 (de) * 1997-07-18 2002-05-23 Hewlett-Packard Co.(A Delaware Corporation), Palo Alto Format zum informationstransfer zwischen geräten
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
BR9907647B1 (pt) * 1998-02-05 2014-04-01 Novartis Ag Novartis S A Novartis Inc Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
PL349863A1 (en) * 1999-02-18 2002-09-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Also Published As

Publication number Publication date
HRP20030677A2 (en) 2004-08-31
NO20033341D0 (no) 2003-07-24
RU2292202C2 (ru) 2007-01-27
WO2002058700A1 (en) 2002-08-01
JP4633331B2 (ja) 2011-02-16
IL156578A0 (en) 2004-01-04
NO335119B1 (no) 2014-09-22
NO20033341L (no) 2003-09-04
CA2434526C (en) 2011-11-01
CA2434526A1 (en) 2002-08-01
PL207720B1 (pl) 2011-01-31
RU2003126170A (ru) 2005-02-27
PL373727A1 (pl) 2005-09-05
AU2002245296B2 (en) 2006-12-21
HRP20030677B1 (en) 2011-10-31
JP2005503323A (ja) 2005-02-03

Similar Documents

Publication Publication Date Title
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
HK1116339A1 (en) Methods of administering epothilone analogs for the treatment of cancer
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL375532A1 (pl) Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IL164599A0 (en) Combination therapy for the treatment of cancer
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
HK1097410A1 (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
EP1613308A4 (en) CANCER TREATMENT METHODS
EP1390029A4 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION
IL159887A0 (en) Combination therapy for the treatment of cancer
MXPA03007423A (es) Derivados de epotilona para tratamiento de tumores refractarios.
MXPA03007394A (es) Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
AU2002304883A1 (en) Device for the treatment of tumours
AU2000263936A1 (en) Substance p analogs for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration